Clinical trials and evidence
Clinical trials and real-world evidence support evidence-based medicine in healthcare, playing a pivotal role in validating and advancing medical treatments and interventions. Clinical trials assess the efficacy and safety of new drugs and therapies, with real-world evidence providing data to inform clinical and regulatory decisions based on empirical data.
Top Stories
-
News
09 Jun 2026
Will obesity drugs save Pfizer from its post-COVID slump?
With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity pipeline. Continue Reading
-
News
08 Jun 2026
Structure's GLP-1 obesity pill could compete with others on the market
Phase 2 data suggests Structure Therapeutics' GLP-1 pill, aleniglipron, could be a potential competitor in the growing market for oral obesity treatments, analysts say. Continue Reading
-
News
23 Feb 2022
Gilead’s HIV-1 Drug Achieves High Rates of Virologic Suppression
Gilead’s HIV-1 capsid inhibitor achieved high rates of virologic suppression and clinically meaningful increases in CD4 counts in a Phase 2/3 trial of individuals with HIV. Continue Reading
-
News
23 Feb 2022
Moderna, ROVI Expand Collaboration to Boost mRNA Vaccines
The companies will increase mRNA manufacturing across ROVI’s facilities in Spain and utilize ROVI’s platform to service future Moderna mRNA vaccine candidates. Continue Reading
-
News
22 Feb 2022
Merck’s Keytruda, Chemotherapy Helps High-Risk Breast Cancer
The estimated three-year event-free survival rates for patients with high-risk breast cancer were 84.5 percent in the Keytruda group and 76.8 percent in the chemotherapy-placebo group. Continue Reading
-
News
21 Feb 2022
AstraZeneca’s Chemotherapy Treatment Improves Prostate Cancer
AstraZeneca’s combination chemotherapy treatment reduced the risk of disease progression or death by a third in metastatic castration-resistant prostate cancer (mCRPC) patients. Continue Reading
-
News
16 Feb 2022
Merck KGaA to Assess Quris AI Platform for Clinical Prediction
Merck KGaA will assess the company’s AI platform with the initial investment focusing on identifying potential liver toxicity risks for drug candidates. Continue Reading
-
News
16 Feb 2022
Biogen, Xbrane Develop Preclinical Monoclonal Antibody, Biosimilar
The preclinical monoclonal antibody and biosimilar candidate has the potential to add another option for patients living with rheumatoid arthritis and other indications Continue Reading
-
News
14 Feb 2022
Abbott Implants Dual-Chamber Leadless Pacemaker in Clinical Trial
The clinical trial will evaluate the safety and efficacy of Abbott's Aveir DR leadless pacemaker in patients across the US, Canada, and Europe indicated for dual-chamber bradycardia pacing. Continue Reading
-
News
14 Feb 2022
Biogen to Develop, Commercialize Genentech’s Bispecific Antibody
Genentech’s bispecific antibody is currently in development to treat individuals with B-cell non-Hodgkin’s lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). Continue Reading
-
News
10 Feb 2022
Pfizer Confirms Positive Date of Lyme Disease Vaccine Candidate
Positive results from the Phase 2 clinical trial of Pfizer’s Lyme disease vaccine candidate support using a three-dose primary series in the planned Phase 3 trial. Continue Reading
-
News
08 Feb 2022
Personalized Immunotherapy Could Treat Metastatic Breast Cancer
In a Phase 2 study, 67% of women generated an immune reaction against their cancer, suggesting that personalized immunotherapy could treat metastatic breast cancer. Continue Reading
-
News
07 Feb 2022
CVS Health, Medable Expand Clinical Trial Access, Engagement
The collaboration will combine Medable’s software platform with CVS Health’s community reach and experienced MinuteClinic providers to boost clinical trial access and engagement. Continue Reading
-
News
01 Feb 2022
Moderna, IAVI Dose First Patients in Trial of HIV Vaccine Antigens
The Phase 1 trial will test whether HIV vaccine antigens can induce specific classes of B-cell responses and guide early maturation toward neutralizing antibody development. Continue Reading
-
News
31 Jan 2022
Opioid Use Disorder Medicine Lacking for Pregnant Women in US Jails
The study found that 39.7% of jails did not allow continuation of opioid use disorder medicine during pregnancy and only 31.9% permitted initiation of OUD medication during pregnancy. Continue Reading
-
News
26 Jan 2022
AstraZeneca Combination Treatment Helps Advanced Biliary Tract Cancer
In a Phase 3 clinical trial, biliary tract cancer patients who received the combination treatment experienced a 20% reduction in the risk of death versus chemotherapy alone. Continue Reading
-
News
26 Jan 2022
NIH Launches Competition to Boost Neuromodulation Therapies
NIH will bridge the gap between early-stage research and clinical use for neuromodulation therapies targeting multiple functions involving the body's internal organs. Continue Reading
-
News
25 Jan 2022
The Center for Breakthrough Medicines, UPenn Boost Gene Therapies
The Center for Breakthrough Medicines and the UPenn Gene Therapy Program partner to advance gene therapies and move therapeutics safely and rapidly from concept to clinic. Continue Reading
-
News
24 Jan 2022
Moderna, Carisma Partner to Develop In Vivo Cancer Therapies
Moderna taps Carisma’s engineered macrophage technology to generate and develop in vivo cancer therapies to expand its oncology pipeline. Continue Reading
-
News
20 Jan 2022
AstraZeneca to Discover Precision Medicines for Undruggable Targets
AstraZeneca and Scorpion Therapeutics will develop precision medicines for undruggable targets using transcription factors to control gene expression and regulate cell processes. Continue Reading
-
News
20 Jan 2022
Pfizer, Beam Focus on Precision Medicine for Rare Diseases
The four-year research collaboration will leverage in vivo technologies to generate a new precision medicine class that targets rare diseases. Continue Reading
-
News
19 Jan 2022
Bristol Myers, Century to Develop Allogeneic Cell Therapies
The first two programs under the partnership will focus on allogeneic cell therapies for acute myeloid leukemia and multiple myeloma. Continue Reading
-
News
18 Jan 2022
Johnson & Johnson Taps Microsoft to Expand Digital Surgery Ecosystem
Microsoft will help Johnson & Johnson advance its digital surgery ecosystem to advance skills, improve workflow, and boost decision-making to increase the overall patient experience. Continue Reading
-
News
17 Jan 2022
Pfizer, Biohaven to Commercialize Small Molecule Migraine Drugs
The companies will bring the small molecule treatment options to the millions of people across the globe suffering from migraines. Continue Reading
-
News
13 Jan 2022
Pfizer Gains Access to LPN Tech For mRNA Vaccines, Therapeutics
Pfizer taps Acuitas Therapeutics for its lipid nanoparticle (LNP) technology to deliver potential new breakthrough mRNA vaccines and therapeutics. Continue Reading
-
News
13 Jan 2022
Sanofi, Exscientia to Research, Develop Small Molecule Drugs
Sanofi and Exscientia will identify and select target small molecule drug candidates for various chronic diseases and diseases with unmet medical needs. Continue Reading
-
News
12 Jan 2022
Real-World Evidence Confirms J&J COVID-19 Vaccine Protection
In the real-world evidence study, Johnson & Johnson’s single-shot COVID-19 vaccine was 81% effective against hospitalizations and 74% effective against breakthrough infections. Continue Reading
-
News
12 Jan 2022
Eli Lilly Enters Partnership for Nucleic Acid Delivery Technology
Eli Lilly & Company gains exclusive rights to Entos Pharmaceuticals’ nucleic acid delivery technology to research and develop proteo-lipid vehicles. Continue Reading
-
News
11 Jan 2022
Moderna Doses First Participant in Study of EBV mRNA Vaccine
The Phase 1 study will enroll nearly 270 participants 18 to 30 years of age to assess the safety and tolerability of Moderna’s Epstein-Barr Virus (EBV) mRNA vaccine candidate. Continue Reading
-
News
11 Jan 2022
Convalescent Plasma Reduces COVID-19 Hospitalizations Nearly 50%
A nationwide trial found that 2.9% of patients who received convalescent plasma required hospitalization within 28 days of their infusion, compared to 6.3% who received placebo. Continue Reading
-
News
10 Jan 2022
Novartis, Alnylam Leverage siRNA Technology for Liver Disease
The companies will leverage siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research. Continue Reading
-
News
04 Jan 2022
South African Study Shows J&J’s COVID-19 Vaccine 85% Effective
J&J’s COVID-19 vaccine effectiveness increased over time from 63% at 0-13 days to 84% at 14-27 days, and 85% at one to two months post-boost. Continue Reading
-
News
30 Dec 2021
FDA Grants Emergency Authorization to Roche’s At-Home COVID-19 Test
The at-home COVID-19 test can produce accurate results in as little as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron. Continue Reading
-
News
29 Dec 2021
Hackensack Meridian Health Supports Immuno-Oncology Platform
Hackensack Meridian Health supports the development of Alloplex Biotherapeutics’ immuno-oncology platform, which brings a highly-differentiated approach to cell therapy development. Continue Reading
-
News
22 Dec 2021
Bristol Myers Squibb Partners for Bispecific T-Cell Candidate
Bristol Myers Squibb enters into an agreement with Immatics for its most advanced bispecific T-cell candidate, IMA401. Continue Reading
-
News
21 Dec 2021
Moderna’s COVID-19 Vaccine Booster Protects Against Omicron
Preliminary trial data shows that Moderna’s COVID-19 vaccine booster neutralized antibody levels against Omicron nearly 37-fold compared to pre-boost levels. Continue Reading
-
News
21 Dec 2021
Kite’s Yescarta Helps High-Risk Large B-Cell Lymphoma Patients
89% of patients receiving Yescarta achieved a complete response, including 78 percent with a complete response at the median follow-up of 15.9 months. Continue Reading
-
News
20 Dec 2021
J&J’s CAR T-Cell Therapy Effective in Multiple Myeloma Patients
About 83% of multiple myeloma patients who received J&J’s CAR T-cell therapy achieved complete response at the 22-month follow-up, an increase from 80% at the 18-month follow-up. Continue Reading
-
News
16 Dec 2021
Roche Launches Platform to Advance Next-Generation Sequencing
The AVENIO Edge System is a scalable, cost-efficient solution for next-generation sequencing laboratories seeking high performance and agility. Continue Reading
-
News
16 Dec 2021
J&J’s COVID-19 Vaccine Booster Increased Antibody, T-Cell Responses
The T-cell response data suggest differences between immune responses following homologous boosting of J&J’s COVID-19 vaccine. Continue Reading
-
News
15 Dec 2021
AstraZeneca Enters Agreement for Transthyretin Amyloidosis Medicine
Eplontersen is currently in Phase 3 development to treat transthyretin amyloidosis, a systemic, progressive, and fatal condition. Continue Reading
-
News
13 Dec 2021
Roche, TIB Molbiol Develop More COVID-19 Tests To Identify Variant
The three COVID-19 test kits will allow differentiation between unique mutations present in the Omicron variant compared to other variants. Continue Reading
-
News
10 Dec 2021
3 Doses of Pfizer’s COVID-19 Vaccine Neutralizes Omicron Variant
In other COVID news, Medicago’s COVID-19 vaccine was 71% effective in a Phase 3 trial and Europe extends Roche’s Actemra authorization to include the treatment of COVID-19. Continue Reading
-
News
09 Dec 2021
GSK, University of Oxford to Uncover Mechanisms of Disease
The Oxford-GSK Institutes of Molecular and Computational Medicine will build on insights from human genetics and leverage advanced technology to unravel mechanisms of disease. Continue Reading
-
News
09 Dec 2021
Thermo Fisher Introduces Protein To Advance CRISPR Gene Editing
The protein eliminates off-target effects compared to wild-type Cas9 in several cell types for more precise CRISPR gene editing. Continue Reading
-
News
08 Dec 2021
GSK Initiative Addresses Key Challenges In Multiple Myeloma Care
Target the Future will provide education on progress in multiple myeloma, identify challenges in the community, and advance solutions to create a better future for patients and caregivers. Continue Reading
-
News
07 Dec 2021
AstraZeneca Unveils $1B Research Facility To Advance Gene-Editing
The Discovery Centre (DISC) in Cambridge, UK, will include advanced robotics, high-throughput screening, and AI-driven technology to advance gene-editing and cell therapies. Continue Reading
-
News
03 Dec 2021
Pfizer, AWS Collaborate To Improve Drug Development, Manufacturing
The collaboration will focus on supporting Pfizer in more rapidly and reliably advancing drug development and evaluating the potential health benefits for patients. Continue Reading
-
News
01 Dec 2021
Moderna Doses First Patients in Phase 2 Study of mRNA RSV Vaccine
Moderna’s mRNA RSV vaccine boosted neutralizing antibody titers against RSV-A nearly 14-fold and against RSV-B nearly 10-fold in a Phase 1 study. Continue Reading
-
News
30 Nov 2021
Pfizer Confirms COVID-19 Vaccine Safety, Efficacy in Adolescents
Pfizer and BioNTech’s COVID-19 vaccine is 100 percent effective in adolescents in a longer-term analysis, with no serious safety concerns identified. Continue Reading
-
News
22 Nov 2021
Moderna’s mRNA Therapeutic Helps Patients With Heart Failure
All patients treated with the mRNA therapeutic had NT-proBNP levels below heart failure limit at six months follow-up, compared to one of four patients who received a placebo. Continue Reading
-
News
17 Nov 2021
Opdivo Plus Chemotherapy Helps Non-Small Cell Lung Cancer Patients
Bristol Myers Squibb’s Opdivo plus chemotherapy improved event-free survival and pathologic complete response in non-small cell lung cancer patients. Continue Reading
-
News
16 Nov 2021
Jardiance Slows Kidney Decline by 40% in Heart Failure Patients
In the Phase 3 trial, Eli Lilly’s Jardiance was well tolerated, consistently improved cardiovascular outcomes, and reduced the risk of death or hospitalization across all heart failure patients. Continue Reading
-
News
11 Nov 2021
GSK’s Daprodustat Effective in Chronic Kidney Disease Patients
Two pivotal Phase 3 trials found that GSK’s drug improved or maintained chronic kidney disease patients within their target hemoglobin range. Continue Reading
-
News
11 Nov 2021
Moderna Enters Partnership To Advance Gene Editing Therapeutics
Moderna and Metagenomi will advance a series of in vivo gene editing therapeutics for patients with serious genetic conditions. Continue Reading
-
News
10 Nov 2021
Gilead, Merck Initiate Phase 2 Study for HIV Treatment in Adults
The Phase 2 study will evaluate the combination HIV treatment, islatravir and lenacapavir, in virologically suppressed individuals living with the disease across 25 sites in the US. Continue Reading
-
News
09 Nov 2021
Abbott Increases Clinical Trial Diversity In Medical Research
Abbott’s new initiative will increase clinical trial diversity in medical research, boosting insights into how different groups respond to new therapies. Continue Reading
-
News
09 Nov 2021
Pfizer’s COVID-19 Treatment Reduces Hospitalization by 89%
In the Phase 2/3 trial, 1% of patients who received Pfizer’s COVID-19 treatment, PAXLOVID, were hospitalized through Day 28, compared to 6.7% of patients in the placebo group. Continue Reading
-
News
04 Nov 2021
Moderna Doses the First Participant in Study of CMV mRNA Vaccine
The Phase 3 study of Moderna’s mRNA vaccine will evaluate the safety and efficacy of the vaccine against primary CMV infection in women ages 16 to 40 years from 150 sites globally. Continue Reading
-
News
03 Nov 2021
Roche Launches Genomic Profiling Kit to Boost Oncology Research
The genomic profile kit analyzes 324 genes across four main alterations known to cause and drive cancer, boosting oncology research and treatment options. Continue Reading
-
News
02 Nov 2021
Collaboration to Study Antibody Drug, Keytruda in Lung Cancer
Daiichi Sankyo, AstraZeneca, and Merck have entered into a second clinical trial collaboration to evaluate a TROP2 directed DXd antibody drug with Merck’s Keytruda in Lung cancer patients. Continue Reading
-
News
01 Nov 2021
Eli Lilly Drug Proves Effective In Adults With Type 2 Diabetes
About 91% of patients receiving the highest dose of Eli Lilly’s tirzepatide saw an A1C reduction of 2.58 percent, compared to 51% of those who received insulin glargine. Continue Reading
-
News
29 Oct 2021
NIH, FDA, 15 Orgs Boost Gene Therapy Development for Rare Diseases
The organizations will accelerate and streamline gene therapy development for rare diseases through the newly launched Bespoke Gene Therapy Consortium. Continue Reading
-
News
27 Oct 2021
Bristol Myers Squibb Reinforces Efficacy of MS Drug, Zeposia
The Phase 3 trial found 75% and 71% of patients receiving Bristol Myers Squibb’s MS drug at 36 and 48 months were relapse-free, respectively. Continue Reading
-
News
27 Oct 2021
FDA Approves Eli Lilly and Company’s Breast Cancer Treatment
FDA based its approval on a Phase 3 trial, which found that patients who received the breast cancer treatment showed significant improvement in invasive disease-free survival. Continue Reading
-
News
26 Oct 2021
Cerner Leverages Real-World Evidence to Advance Therapies
Cerner’s new operating unit, Cerner Enviza, clarifies data through real-world evidence to get therapies to patients more quickly at a lower cost. Continue Reading
-
News
26 Oct 2021
Two Doses of Moderna’s COVID-19 Vaccine Effective in Children
In the Phase 2/3 trial, two 50-microgram doses of Moderna’s COVID-19 vaccine elicited robust neutralizing antibody response and a favorable safety profile. Continue Reading
-
News
25 Oct 2021
Pfizer, BioNTech COVID-19 Vaccine Booster Dose 95.6% Effective
In the randomized, Phase 3 clinical trial, there were five cases of the coronavirus in the COVID-19 vaccine booster dose and 109 cases in the placebo group. Continue Reading
-
News
20 Oct 2021
FDA Awards $25M in Grants to Clinical Trials Studying Rare Diseases
FDA awards the funding to clinical investigators to support studies that address unmet needs of various rare diseases and conditions or provide improvements in treatment in diagnosis. Continue Reading
-
News
15 Oct 2021
AstraZeneca’s COVID-19 Antibody Prevents and Treats COVID-19
In other COVID news, Gavi purchases an additional 176.5 million doses of Moderna’s COVID-19 vaccine and the complete Phase 3 results of Novavax’s vaccine have been published. Continue Reading
-
News
14 Oct 2021
WHO Recommends Broad Roll-Out of GSK’s Malaria Vaccine For Children
GSK’s malaria vaccine, RTS,S is the first and only malaria vaccine studied in pivotal long-term trials that significantly reduces malaria in children. Continue Reading
-
News
13 Oct 2021
J&J’s Early-Stage Compound Shows Promise Against Dengue Virus
Pre-clinical data showed that the early-stage compound prevents the interaction between two viral proteins that play a role in the replication process of the dengue virus. Continue Reading
-
News
07 Oct 2021
J&J Submits Data to FDA to Support COVID-19 Vaccine Booster
A Phase 3 study found that Johnson & Johnson’s COVID-19 vaccine booster elicited 94% protection against the coronavirus. Continue Reading
-
News
06 Oct 2021
Johnson & Johnson Launches Phase 3 Trial of RSV Vaccine in Adults
The Phase 3 study will enroll individuals 60 years of age and older to receive either one dose of the RSV vaccine or a placebo. Researchers will follow patients for at least two RSV seasons. Continue Reading
-
News
05 Oct 2021
AstraZeneca Requests FDA EUA for COVID-19 Antibody Combination
If granted, AZD7442 will be the first long-acting COVID-19 antibody combination to receive emergency use authorization for coronavirus prevention. Continue Reading
-
News
04 Oct 2021
J&J’s Xarelto Evokes Fewer Blood Clots in Patients Than Aspirin
Pediatric patients treated with Johnson & Johnson’s Xarelto had a slightly lower prevalence of non-major clinically relevant bleeding and minimal bleeding than aspirin. Continue Reading
-
News
04 Oct 2021
Regeneron’s COVID-19 Antibody Cocktail Helps Hospitalized Patients
Regeneron’s COVID-19 antibody cocktail reduced patients’ risk of dying by 36 percent within 29 days of receiving treatment. Continue Reading
-
News
01 Oct 2021
Pfizer Submits Data to FDA For COVID-19 Vaccine in Children
Initial trial data found that the two-dose COVID-19 vaccine regimen in children elicited neutralizing antibody responses one month after the second dose. Continue Reading
-
News
30 Sep 2021
FDA Approves Abbott’s Epic Plus for Aortic Valve Disease
Abbott’s Epic Plus and Epic Plus Supra Stented Tissue Valve have shown strong clinical outcomes and enhance therapy options for people with mitral and aortic valve disease. Continue Reading
-
News
29 Sep 2021
Pfizer Launches Trial of COVID-19 Treatment for Post-Exposure
The trial will evaluate Pfizer’s COVID-19 treatment with a low dose of ritonavir in healthy adults living in the same household as an individual with confirmed symptomatic disease. Continue Reading
-
News
29 Sep 2021
AstraZeneca Invests in VaxEquity for saRNA Therapeutics Platform
The long-term research collaboration will optimize VaxEquity’s saRNA platform to target novel pathways not amendable to traditional drug discovery. Continue Reading
-
News
28 Sep 2021
Improving Adult Vaccination Rates, Health Outcomes Globally
In a new survey, 19.8% of adult participants were up to date on recommended vaccines for adults, with many people wanting more clear information on necessary vaccines. Continue Reading
-
News
28 Sep 2021
Roche’s Tecentriq Benefits Non-Small Cell Lung Cancer Patients
Tecentriq administered after surgery and chemotherapy reduced the risk of disease recurrence or death by 34 percent in individuals with Stage II-IIA non-small cell lung cancer. Continue Reading
-
News
27 Sep 2021
SAS, UNC-Chapel Hill to Transform Antiviral Drug Development
SAS and UNC-Chapel Hill will work together to accelerate antiviral drug development, initially addressing new treatments for COVID-19. Continue Reading
-
News
23 Sep 2021
AbbVie Helps to Advance Gene Therapy for Chronic Retinal Diseases
AbbVie and Regenxbio will complete ongoing clinical trials of the gene therapy in patients with chronic retinal diseases, including wet AMD and diabetic retinopathy. Continue Reading
-
News
23 Sep 2021
FDA Authorizes Booster Dose of Pfizer, BioNTech COVID-19 Vaccine
After approving the COVID-19 vaccine last month, FDA authorized a booster dose six months after completion of the primary vaccination series based on scientific evidence. Continue Reading
-
News
21 Sep 2021
Second Dose of J&J’s COVID-19 Vaccine 94% Effective
The Phase 3 trial found that a booster shot of J&J’s single-dose COVID-19 vaccine was highly effective at protecting against the coronavirus and related adverse events, such as hospitalization and death. Continue Reading
-
News
21 Sep 2021
J&J’s Ebola Vaccine Generates Robust Antibody Responses
Johnson & Johnson’s Ebola vaccine regimen induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98% of all patients. Continue Reading
-
News
20 Sep 2021
FDA Grants Breakthrough Designation for Eli Lilly’s Diabetes Drug
In a Phase 3 trial, Eli Lilly’s diabetes drug elicited a 21% percent relative risk reduction for cardiovascular death or hospitalization for heart failure compared to placebo. Continue Reading
-
News
20 Sep 2021
Pfizer, BioNTech COVID-19 Vaccine Effective in Pediatric Patients
The COVID-19 vaccine elicited a neutralizing antibody geometric mean titer of 1,197 in pediatric patients, demonstrating strong immune response one month after the second dose. Continue Reading
-
News
17 Sep 2021
Providers Hopeful of Immunotherapy to Treat Early-Stage Cancer
In a new Bristol Myers Squibb survey, most healthcare providers were hopeful of the potential of immunotherapy for earlier-stage cancer treatment, especially in lung cancer and melanoma. Continue Reading
-
News
15 Sep 2021
FDA Accepts Novartis BLA for Monoclonal Antibody in ESCC
Novartis submitted its application based on Phase 3 Rationale 302 trial data that found the antibody reduced the risk of death in patients by 30 percent. Continue Reading
-
News
13 Sep 2021
Pfizer Initiates Phase 3 Clinical Trial of RSV Vaccine in Adults
The placebo-controlled Phase 3 clinical trial will evaluate a single dose of Pfizer’s RSV vaccine candidate in adults 60 years of age and older. Continue Reading
-
News
13 Sep 2021
Medidata, Labcorp Collaborate to Boost Digital Biomarker Discovery
The companies will leverage Medidata Sensor Cloud to process sensor data within clinical trials and enhance digital biomarker discovery for medical devices and therapeutic areas. Continue Reading
-
News
13 Sep 2021
Moderna, ILCM to Develop mRNA Therapeutic for Ultra-Rare Disease
The mrRNA therapeutic, mRNA-3351, is designed to restore the missing proteins that cause CN-1. The companies aim to make the therapy available to patients at no cost. Continue Reading
-
News
10 Sep 2021
3 Use Cases for Real World Evidence in Pharma Drug Development
Real-world evidence (RWE) plays an essential role in pharmaceutical drug development by helping researchers identify potential patients and create the right criteria for clinical trials. Continue Reading
-
News
09 Sep 2021
Eli Lilly’s Jardiance Reduces Death for Heart Failure Patients
Jardiance also reduced the relative risk of first and recurrent hospitalizations for heart failure patients by 27% and substantially slowed kidney function decline. Continue Reading
-
News
08 Sep 2021
Thermo Fisher, AstraZeneca to Develop NGS-Based Targeted Therapies
The companies will develop next-generation sequencing (NGS)-based targeted therapies to support AstraZeneca’s pipeline of precision medicines. Continue Reading
-
News
07 Sep 2021
Cardiovascular Disease Clinical Trials Still Lack Diversity
A new paper found that half of the cardiovascular clinical trials examined in a study enrolled less than 25% of Black participants. Continue Reading
-
News
06 Sep 2021
Eli Lilly, Lycia Collaborate to Discover Targeted Drug Candidates
The multi-year research collaboration will leverage the lysosomal targeting chimera platform to discover and develop novel targeted drug candidates across various areas and diseases. Continue Reading
-
News
01 Sep 2021
Merck’s Pneumococcal Vaccine Meets Key Endpoints in Phase 3 Trial
Merck’s pneumococcal vaccine, Vaxneuvance, elicited a safety profile compared to the licensed 13-valent pneumococcal conjugate vaccine in infants 42 to 90 days of age. Continue Reading
-
News
31 Aug 2021
COVID-19 Convalescent Plasma Fails to Halt Disease Progression
A recent NEJM study found that coronavirus disease progression occurred in 30% of patients in the COVID-19 convalescent plasma group and 31.9% in the placebo group. Continue Reading